Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia

Trial Profile

A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 07 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top